pharma · Hyperphagia · Bariatric Surgery · AARD
Ark Therapeutics
Ark Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2025
- Employees
- 4
- Programs
- 6
- Drugs
- 5
- Patents
- 7
Ark Therapeutics patents
7 pharmaceutical patents indexed for Ark Therapeutics. 0 expire within 24 months.
Ark Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12427125
Method for treating SARS and treating or preventing ARDS
granted -
US 12414934
Combination therapies
granted -
US 12329739
Isoflavonoid compounds and methods for the treatment of cancer
granted -
US 12318364
Isoflavonoid compositions and methods for the treatment of cancer
granted -
US 12268660
Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension
granted -
US 12201593
Oral pharmaceutical formulations of bitter compounds for asthma
granted -
US 10835505
Oral pharmaceutical formulation for weight loss, diabetes and related disorders
granted
Frequently asked questions
How many patents does Ark Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Ark Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.